An increasing number of studies have confirmed that inhibiting the AKT and ERK pathways could increase the radiosensitivity of tumor cells in vivo and in vitro (Fumarola et al., 2014; Leszczynska et al., 2015). Here, AKT1 is linked to neoplasm.